Breast cancer: current and future endocrine therapies
C Palmieri, DK Patten, A Januszewski… - Molecular and cellular …, 2014 - Elsevier
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
Breast cancer: Current and future endocrine therapies
C Palmieri, DK Patten… - Molecular and …, 2014 - research.manchester.ac.uk
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5. years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5. years of adjuvant tamoxifen has improved survival rates …
Breast cancer: current and future endocrine therapies.
C Palmieri, DK Patten, A Januszewski… - Molecular and …, 2013 - europepmc.org
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
Breast cancer: Current and future endocrine therapies
C Palmieri, DK Patten, A Januszewski… - Molecular and Cellular …, 2014 - infona.pl
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5years of adjuvant tamoxifen has improved survival rates …
[PDF][PDF] Breast cancer: Current and future endocrine therapies
C Palmieri, DK Patten, A Januszewski… - Molecular and Cellular …, 2014 - academia.edu
abstract Endocrine therapy forms a central modality in the treatment of estrogen receptor
positive breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved …
positive breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved …
Breast cancer: current and future endocrine therapies.
C Palmieri, D Patten, A Januszewski, G Zucchini… - 2014 - christie.openrepository.com
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
[PDF][PDF] Breast cancer: Current and future endocrine therapies
C Palmieri, DK Patten, A Januszewski… - Molecular and …, 2014 - researchgate.net
abstract Endocrine therapy forms a central modality in the treatment of estrogen receptor
positive breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved …
positive breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved …
Breast cancer: current and future endocrine therapies
C Palmieri, DK Patten… - Molecular and …, 2014 - pubmed.ncbi.nlm.nih.gov
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …
breast cancer. The routine use of 5 years of adjuvant tamoxifen has improved survival rates …